Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04983901 · ClinicalTrials.gov registry record · Phase 2
Phase II Single-center, Randomized, Open-label, Prospective, Study TO Determine THE Impact OF Serial Procalcitonin
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT04983901: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT04983901 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04983901, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This phase II trial studies the effect of imipenem-relebactam in treating patients with cancer who have a fever due to low white blood cell counts (febrile neutropenia). In this study, imipenem-relebactam will be compared to the standard-of-care treatment (cefepime, meropenem, or piperacillin/tazobactam) for the treatment of febrile neutropenia. Imipenem-relebactam is used to treat infections. Giving imipenem-relebactam may help to control febrile neutropenia in patients with cancer.
Interventions
- DRUG Vancomycin
- DRUG Cefepime
- DRUG Meropenem
- DRUG Imipenem/Cilastatin/Relebactam
- DRUG Piperacillin-Tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2023-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04983901
The ClinicalTrials.gov registry entry for NCT04983901 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vancomycin is the first listed.
NCT04983901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04983901 about?
NCT04983901 is a clinical study titled "Phase II Single-center, Randomized, Open-label, Prospective, Study TO Determine THE Impact OF Serial Procalcitonin". This phase II trial studies the effect of imipenem-relebactam in treating patients with cancer who have a fever due to low white blood cell counts (febrile neutropenia). In this study, imipenem-relebactam will be compared to the standard-of-care treatment (cefepime, meropenem, or piperacillin/tazoba...
What is the current status of trial NCT04983901?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2021-09-14. Estimated completion is 2023-10-06.
What interventions are being tested in trial NCT04983901?
The interventions under investigation include: Vancomycin (DRUG), Cefepime (DRUG), Meropenem (DRUG), Imipenem/Cilastatin/Relebactam (DRUG), Piperacillin-Tazobactam (DRUG).
Who is sponsoring clinical trial NCT04983901?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.